NCT07615985尚未招募1 期
A Phase 1a, First-in-human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PMG1016 in Healthy Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 30
- 试验地点
- 1
研究概览
简要总结
This study is a first-in-human (FIH), randomized, double-blind, placebo-controlled study of PMG1016 in healthy adult participants. It aims to investigate the safety, tolerability, PK, and immunogenicity of PMG1016 administered via IV infusion.
Cohort 1: Healthy participants receiving single doses of PMG1016 Dose 1 or placebo.
Cohort 2: Healthy participants receiving single doses of PMG1016 Dose 2 or placebo.
Cohort 3: Healthy participants receiving single doses of PMG1016 Dose 3 or placebo.
Cohort 4: Healthy participants receiving single doses of PMG1016 Dose 4 or placebo.
详细描述
Participants will be enrolled and randomized into 1 of 4 cohorts in a double-blind manner
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants must be in good health based on medical history, physical exam, vital signs, ECG, and lab results at screening, as judged by the PI.
- •BMI 17.5-32.0 kg/m² and body weight 50-100 kg for males or 45-100 kg for females
- •No clinically significant lab abnormalities (hematology, coagulation, biochemistry, urinalysis) per PI discretion
- •Females: Must be non-pregnant, non-lactating, and use double contraception (condom + hormonal method/vaginal ring/IUD) through study completion, unless surgically sterile, postmenopausal, or in same-sex relationships. Negative pregnancy tests required. No oocyte donation for 90 days post dose.
- •Males: Must be surgically sterile, abstinent, or use condoms plus a highly effective method for female partners. Vasectomized males without proof of azoospermia must use condoms with WOCBP partners. No sperm donation for 90 days post dose.
排除标准
- •History or evidence of any clinically significant medical condition (e.g., cardiovascular, gastrointestinal, endocrine, hematologic, psychiatric, renal, musculoskeletal, infectious, neurological, or other major disease) as determined by the PI.
- •A PR <40 or >100 bpm or mean SBP >140 mmHg or DBP >95 mmHg (based on triplicate supine measurements after 5 minutes' rest).
- •Mean QTcF >450 ms (males) or >470 ms (females) at Screening; one repeat triplicate ECG allowed at PI discretion
- •Any clinically significant ECG abnormalities (rhythm, conduction, morphology) that may affect QTc interpretation, per PI judgment
- •ALT, AST, or creatinine >1.5 × ULN, or total bilirubin or lymphocytes > ULN.
- •Hemoglobin (HGB) below the lower limit of the normal range (ULN) prior to enrollment.
- •Participants with a positive toxicology screening panel or positive alcohol breath test at Screening and on Day -
- •Regular alcohol consumption defined as > 21 alcohol units per week. Participant is unwilling to abstain from alcohol beginning 48 hours prior to admission to the CRU and while residing at the CRU.
- •Blood donation or significant blood loss (≥500 mL) within 60 days prior to the first IP administration.
- •Plasma donation within 7 days prior to the first IP administration.
- •Use of any investigational product/device within 30 days or 5 half-lives (whichever is longer), or participation in >4 investigational drug studies in the past year.
- •Pregnant or lactating at Screening or planning pregnancy (self or partner) during the study or follow-up.
- •Fever >37.5°C or symptomatic infection within 2 weeks before Screening; any infection requiring systemic antibiotics within 3 months; history of recurrent infections; or a positive SARS-CoV-2 PCR before CRU admission.
- •Active malignancy, history of malignancy, or untreated precancerous lesions. Adequately treated or fully excised precancerous lesions are allowed.
- •Participants with a known history of retinal diseases, including conditions such as prior retinal detachment.
- •Participants with a history of recurrent epistaxis or gingival bleeding.
- •Use of prescription medications (except hormonal contraception) within 2 weeks before dosing; mAb products within 5 half-lives; or OTC drugs, supplements, or herbal products within 7 days before dosing.
- •History of anaphylaxis or severe allergy per PI judgment; mild untreated hay fever may be allowed.
- •History of allergic reaction or hypersensitivity to any of the excipients in the IP.
- •Positive screening test for HIV-1/2, HBsAg, HCV antibody, or syphilis.
- •Any condition that, in the PI's judgment, may pose a risk to the participant or the study.
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 TabletSafetyTolerabilityPharmacokineticsNCT07285967Hangzhou Yirui Pharmaceutical Technology Co., Ltd64
进行中（未招募）
3 期
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsNCT07427797Ipsen309
招募中
1 期
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.COVID -19NCT07445971ModeX Therapeutics, An OPKO Health Company80
招募中
2 期
A first-in-human clinical study of PBP1510 in patients with pancreatic cancer.2024-514379-16-00Prestige Biopharma Ltd35
招募中
1 期
A Study to Evaluate ALN-2232 in Participants With ObesityObesityNCT07463846Alnylam Pharmaceuticals156